As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

As As­traZeneca re­ports third-quar­ter rev­enue of al­most $11.5 bil­lion and rais­es its full-year guid­ance, the com­pa­ny is tout­ing a “favourable mix of sales” from its on­col­o­gy and rare dis­ease med­i­cines.

In a state­ment, CEO Pas­cal So­ri­ot tout­ed “strong growth tra­jec­to­ry” giv­en that the com­pa­ny booked ze­ro sales of its Covid-19 vac­cine and an­ti­bod­ies. Rev­enue growth was 5%, but when ex­clud­ing Covid-19 med­i­cines, it’s 12%. He al­so high­light­ed sev­er­al Phase III tri­al launch­es, in­clud­ing for vol­rus­tomig, a PD-1/CT­LA-4 bis­pe­cif­ic an­ti­body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER